Cox Capital Mgt LLC Decreases Stake in Abbott Laboratories $ABT

Cox Capital Mgt LLC cut its stake in shares of Abbott Laboratories (NYSE:ABT) by 23.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 27,827 shares of the healthcare product maker’s stock after selling 8,631 shares during the quarter. Abbott Laboratories comprises about 2.2% of Cox Capital Mgt LLC’s investment portfolio, making the stock its 17th largest position. Cox Capital Mgt LLC’s holdings in Abbott Laboratories were worth $3,459,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Carr Financial Group Corp grew its position in Abbott Laboratories by 2.0% during the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after buying an additional 76 shares during the period. Gemmer Asset Management LLC lifted its position in shares of Abbott Laboratories by 2.9% during the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock valued at $368,000 after acquiring an additional 78 shares during the period. Global Financial Private Client LLC boosted its stake in shares of Abbott Laboratories by 3.3% during the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after acquiring an additional 79 shares in the last quarter. Citizens & Northern Corp grew its holdings in shares of Abbott Laboratories by 0.4% in the 3rd quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock worth $2,930,000 after acquiring an additional 79 shares during the period. Finally, American National Bank of Texas increased its stake in Abbott Laboratories by 2.4% in the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock valued at $427,000 after purchasing an additional 79 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ABT. Daiwa Securities Group dropped their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Evercore lowered their price objective on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Citigroup dropped their target price on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. The Goldman Sachs Group cut their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Finally, Barclays dropped their price target on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $136.16.

Abbott Laboratories Stock Down 0.4%

ABT opened at $104.12 on Friday. Abbott Laboratories has a 12 month low of $102.41 and a 12 month high of $139.06. The business has a 50-day moving average of $110.82 and a two-hundred day moving average of $122.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The stock has a market capitalization of $181.35 billion, a price-to-earnings ratio of 27.99, a price-to-earnings-growth ratio of 1.65 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period in the previous year, the firm earned $1.34 earnings per share. Abbott Laboratories’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. Abbott Laboratories’s payout ratio is 67.74%.

Insider Activity

In other news, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Eric Shroff sold 709 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the sale, the senior vice president owned 39,164 shares in the company, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock worth $353,097 over the last quarter. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.